Soleno Therapeutics, Inc. SLNO R2K

Healthcare · Biotechnology · United States

Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California. As of May 18, 2026, Soleno Therapeutics, Inc. operates as a subsidiary of Neurocrine Biosciences, Inc.

Market & Price

Market Cap

$2.76B

Current Price

$53.01

High / Low (52W)

$88.49 / $30.05

Beta

-2.22

Valuation

Stock P/E

27.47

Industry PE

23.65

Forward P/E

PEG Ratio

Book Value

$8.61

Price to Book

6.16

P/S

9.69

EV/EBITDA

27.99

Dividend Yield

Profitability & Returns

ROCE

5.25%

ROE

26.38%

ROA

12.07%

Profit Margin

33.70%

Op Margin

33.57%

EPS (Latest Qtr)

$0.59

EPS (TTM)

$1.93

Balance Sheet & Liquidity

Debt/Equity

0.11

Quick Ratio

5.21

Current Ratio

5.62

Debt

$54.28M

Total Assets

$563.83M

Current Assets

$355.81M

Working Capital

$294.45M

Ownership

Promoter Holding

1.31%

Chg in Prom Hold

FII / Inst Holding

111.53%

Chg in FII Hold

Financial Snapshot

Enterprise Value

$2.56B

Total Revenue (TTM)

$285.01M

EBITDA

$91.52M

Free Cash Flow

$91.67M

Operating Cash Flow

$105.53M

Shares Outstanding

52.12M

Gross Margin

98.63%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

Profit 5Y

62.27%

Revenue (YoY)

Earnings (YoY)

PROS

Strong return on equity of 26.4%.
Excellent profit margin of 33.7%.
Profit CAGR of 62.3% over 5 years.
Generates positive free cash flow.

CONS

Trading 40.1% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).
RSI at 78 suggests overbought conditions.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	SLNO Soleno Therapeutics, Inc. R2K	53.01	27.47	$2.76B	-	5.25%	26.38%	-	62.27%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Sep 2013	Mar 2014	Jun 2014	Sep 2014	Mar 2015	Jun 2015	Sep 2015	Mar 2016	Jun 2016	Sep 2016	Mar 2017	Jun 2017	Sep 2017	Mar 2018	Jun 2018	Sep 2018	Mar 2019	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	22.00K	97.00K	247.00K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	32.66M	66.02M	91.73M	94.60M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	696.00K	1.14M	863.00K	1.20M
Gross Profit	-	-	-	-	4.00K	75.00K	191.00K	-14.00K	-49.00K	-70.00K	56.00K	-41.00K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	31.96M	64.88M	90.87M	93.41M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	42.78M	37.38M	42.16M	50.44M	61.64M
Operating Income	-993.00K	-684.00K	-1.31M	-1.32M	-2.43M	-3.04M	-3.18M	-4.26M	-2.29M	-1.97M	-1.37M	-2.97M	-2.63M	-3.48M	-3.41M	-3.88M	-4.98M	-5.62M	-6.13M	-9.28M	-11.19M	-7.86M	-9.16M	-11.09M	-8.29M	-5.77M	-6.78M	-6.24M	-8.47M	-8.62M	-10.38M	-23.48M	-24.87M	-	-	-42.78M	-5.42M	22.72M	40.43M	31.76M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-41.91M	-2.83M	27.91M	45.22M	36.72M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.36M	1.38M	1.39M	1.35M	1.29M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-43.77M	-4.71M	26.01M	43.36M	34.91M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.54M
Net Income	-1.59M	-834.00K	-2.79M	-2.39M	-11.65M	1.88M	-3.29M	-3.19M	-3.51M	-2.75M	-2.89M	-3.97M	-3.79M	-3.80M	-7.06M	-2.74M	-7.03M	-10.01M	889.00K	-5.86M	-7.38M	-8.54M	-8.95M	-10.99M	-8.14M	-5.72M	-6.72M	-6.13M	-8.36M	-8.47M	-10.86M	-21.40M	-21.85M	-	-	-43.77M	-4.71M	26.01M	43.36M	31.38M
Diluted EPS	-	-	-5.21	-	-	0.25	-	-	-0.23	-	-	-	-	-	-	-0.13	-	-	-0.19	-	-	-0.11	-	-0.14	-1.53	-1.07	-0.72	-0.65	-0.88	-0.81	-0.95	-0.59	-0.57	-	-	-0.95	-0.09	0.47	0.80	0.59
R&D Expense	745.00K	372.00K	549.00K	717.00K	878.00K	1.18M	1.19M	1.77M	658.00K	708.00K	327.00K	773.00K	946.00K	1.18M	1.71M	2.09M	2.76M	3.75M	4.49M	6.70M	6.10M	4.83M	7.16M	5.59M	4.97M	3.99M	3.70M	3.77M	5.32M	5.14M	6.04M	14.60M	12.34M	30.14M	-	13.52M	9.15M	8.40M	-	11.27M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	3.00M	0	607.47K	1.45M	-	-	-	-	-	0	0	0	190.41M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	0	0	2.70M
Gross Profit	-	0	254.79K	-58.52K	-	-	-	-	-	-	0	0	187.71M
Operating Expenses	-	-	-	-	-	-	-	-	-	25.11M	38.67M	184.43M	172.75M
Operating Income	-846.78K	-5.16M	-12.16M	-8.32M	-12.17M	-14.30M	-23.49M	-36.29M	-	-25.11M	-38.67M	-184.43M	14.95M
EBITDA	-	-	-	-	-	-	-	-	-	-22.10M	-37.03M	-173.63M	28.38M
Interest Expense	-	-	-	-	-	-	-	-	-	0	0	231.00K	5.48M
Pretax Income	-	-	-	-	-	-	-	-	-	-24.07M	-38.99M	-175.85M	20.89M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-3.71M	-13.24M	-15.91M	-12.07M	-15.38M	-13.34M	-30.77M	-24.64M	-	-24.07M	-38.99M	-175.85M	20.89M
Diluted EPS	-	-	-	-	-	-	-	-	-	-2.87	-2.36	-4.38	0.39
R&D Expense	2.38M	2.24M	4.54M	2.25M	3.07M	7.18M	16.27M	23.19M	21.45M	15.27M	25.19M	78.57M	40.63M

Compounded Sales Growth

5 Years:	-
1 Year:	-

Compounded Profit Growth

5 Years:	62.27%
1 Year:	-

Stock Price Performance

1 Year:	-27.73%
6 Months:	+11.95%
3 Months:	+37.69%
1 Month:	+0.44%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Mar 2018	Jun 2018	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	1.59M	8.40M	8.20M	5.56M	39.02M	-	-	43.15M	38.17M	64.98M	-	26.50M	180.69M	330.97M	563.83M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	15.65M	171.36M	293.89M	355.81M
Cash & Equivalents	2.16M	1.27M	7.96M	5.49M	2.73M	17.10M	-	-	23.10M	20.73M	49.22M	-	14.60M	169.68M	87.93M	70.11M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	15.02M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	28.21M
Total Liabilities	-	-	-	4.98M	2.13M	12.21M	13.08M	16.70M	12.74M	23.23M	19.43M	-	16.15M	23.18M	85.86M	113.72M
Current Liabilities	-	14.18M	1.29M	3.19M	1.71M	1.73M	-	-	1.88M	4.96M	8.62M	-	7.31M	11.51M	18.75M	61.36M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	49.83M	49.86M
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	155.00K	403.00K	52.83M	52.55M
Total Equity	-34.20M	-34.20M	-11.19M	3.22M	3.44M	26.82M	-	-	30.41M	14.95M	45.55M	-	10.35M	157.51M	245.11M	450.12M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	8.16M	31.68M	45.70M	52.29M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	-4.48M	-10.30M	-13.50M	-9.95M	-11.68M	-17.38M	-25.22M	-	-20.78M	-24.94M	-69.10M	46.80M
Investing Cash Flow	-	-30.68K	-1.32M	-38.68K	154.00K	-180.00K	528.00K	-7.00K	-	-13.00K	0	-225.68M	-201.78M
Financing Cash Flow	-	11.20M	9.16M	10.77M	24.17M	17.83M	14.48M	53.72M	-	14.09M	180.02M	213.03M	137.16M
Capital Expenditure	-1.27K	-30.68K	-55.78K	-14.79K	-2.00K	-8.00K	-21.00K	-7.00K	-22.00K	-13.00K	-	-218.00K	-73.00K
Free Cash Flow	-	-4.52M	-10.36M	-13.51M	-9.95M	-11.69M	-17.40M	-25.23M	-	-20.79M	-24.94M	-69.31M	46.73M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-6.70M	155.08M	-81.75M	-17.82M
Share Buybacks	-	-	-	-	-	-	-	-	-	-	0	0	100.15M

Ratios (Annual)

Figures in %.

Metric	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	41.9%	-4.0%	-	-	-	-	-	-	-	-	98.6%
Operating Margin %	-28.2%	-	-2,001.7%	-573.8%	-	-	-	-	-	-	-	-	7.9%
Net Margin %	-123.6%	-	-2,618.8%	-831.6%	-	-	-	-	-	-	-	-	11.0%
ROE %	10.8%	118.3%	-493.5%	-351.2%	-57.4%	-43.8%	-205.9%	-54.1%	-	-232.6%	-24.8%	-71.7%	4.6%
ROCE %	6.7%	-72.6%	-242.8%	-215.8%	-32.6%	-34.6%	-70.7%	-64.4%	-	-130.9%	-22.9%	-59.1%	3.0%

Shareholding Pattern

Insiders

1.31%

Institutions

111.53%

Public Float

113.01%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Janus Henderson Group PLC	13.62%	7.10M	$376.34M
2	FMR, LLC	11.11%	5.79M	$306.84M
3	Wellington Management Group, LLP	8.49%	4.43M	$234.66M
4	Blackrock Inc.	7.18%	3.74M	$198.40M
5	State Street Corporation	5.14%	2.68M	$142.11M
6	Avoro Capital Advisors LLC	4.41%	2.30M	$121.92M
7	Vanguard Capital Management LLC	4.13%	2.15M	$114.14M
8	Nantahala Capital Management, LLC	3.35%	1.74M	$92.46M
9	Polar Capital Holdings PLC	3.26%	1.70M	$90.06M
10	Khrom Capital Management LLC	2.90%	1.51M	$80.12M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SLNO

No recent headlines available.

SLNO · Healthcare